Business
Japanese government panel endorses Sumitomo Pharma's iPS-derived treatment for Parkinson's
Japanese government panel endorses Sumitomo Pharma's iPS-derived treatment for Parkinson's
About this update from Cuorips Inc.
Japan's health ministry said on Thursday a panel of specialists had endorsed Sumitomo Pharma's TSE:4506 iPS cell-derived treatment for Parkinson's disease, paving the way for the world's first medical products based on the technology.So-called iPS cells, or induced pluripotent stem cells, have the capacity to change into various cells in the body. Japanese scientist Shinya Yamanaka won the Nobel Prize in 2012 for creating such cells. The panel also gave its endorsement to Cuorips's TSE:4894 iPS cell-derived cardiomyocyte patches for the treatment of severe heart failure.Health Minister Kenichiro Ueno is expected to give his official approval for the two companies' products "soon", the Mainichi Shimbun daily said.